CN104837821B - 作为谷氨酰胺转移酶的抑制剂的酰基哌嗪类及其在药物中的用途 - Google Patents

作为谷氨酰胺转移酶的抑制剂的酰基哌嗪类及其在药物中的用途 Download PDF

Info

Publication number
CN104837821B
CN104837821B CN201380052683.9A CN201380052683A CN104837821B CN 104837821 B CN104837821 B CN 104837821B CN 201380052683 A CN201380052683 A CN 201380052683A CN 104837821 B CN104837821 B CN 104837821B
Authority
CN
China
Prior art keywords
group
compound
nmr
cdcl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380052683.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104837821A (zh
Inventor
M·格里芬
D·拉思伯恩
L·E·巴达诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aston University
Original Assignee
Aston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aston University filed Critical Aston University
Publication of CN104837821A publication Critical patent/CN104837821A/zh
Application granted granted Critical
Publication of CN104837821B publication Critical patent/CN104837821B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380052683.9A 2012-10-09 2013-10-09 作为谷氨酰胺转移酶的抑制剂的酰基哌嗪类及其在药物中的用途 Active CN104837821B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1218084.0A GB201218084D0 (en) 2012-10-09 2012-10-09 Novel compounds and methods for use in medicine
GB1218084.0 2012-10-09
PCT/GB2013/052631 WO2014057266A1 (en) 2012-10-09 2013-10-09 Acylpiperazines as inhibitors of transglutaminase and their use in medicine

Publications (2)

Publication Number Publication Date
CN104837821A CN104837821A (zh) 2015-08-12
CN104837821B true CN104837821B (zh) 2018-11-13

Family

ID=47294510

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380052683.9A Active CN104837821B (zh) 2012-10-09 2013-10-09 作为谷氨酰胺转移酶的抑制剂的酰基哌嗪类及其在药物中的用途

Country Status (6)

Country Link
US (1) US9656978B2 (enExample)
EP (1) EP2906543B1 (enExample)
JP (1) JP6138950B2 (enExample)
CN (1) CN104837821B (enExample)
GB (1) GB201218084D0 (enExample)
WO (1) WO2014057266A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201218084D0 (en) 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine
EP3607948A1 (en) 2018-08-07 2020-02-12 Aarhus Universitet Tissue transglutaminase modulators for medicinal use
WO2022213198A1 (en) * 2021-04-08 2022-10-13 University Of Ottawa Arylacetyl inhibitors of tg2 and uses thereof
WO2023135425A1 (en) * 2022-01-13 2023-07-20 Aston University Inhibitors of transglutaminase
GB202310246D0 (en) 2023-07-04 2023-08-16 Univ Aston New compounds
GB202310233D0 (en) 2023-07-04 2023-08-16 Univ Aston New compounds
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411909A1 (en) * 1989-07-31 1991-02-06 Merck & Co. Inc. Imidazole compounds and their use as transglutaminase inhibitors
WO1996030378A1 (en) * 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Bisphosphonic acid derivatives
EP0771565A2 (en) * 1995-10-25 1997-05-07 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
US5721365A (en) * 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
EP0838460A1 (en) * 1995-07-13 1998-04-29 Senju Pharmaceutical Co., Ltd. Piperazine derivatives and use of the same
US6030946A (en) * 1995-06-07 2000-02-29 Axys Pharmaceuticals, Inc. Reversible cysteine protease inhibitors
WO2001007440A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Imidazoimidazoles and triazoles as anti-inflammatory agents
CN1293666A (zh) * 1998-03-17 2001-05-02 阿斯特拉曾尼卡有限公司 苯硫酰胺衍生物及其作为药物的用途
WO2004089470A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2013022550A2 (en) * 2011-08-10 2013-02-14 President And Fellows Of Harvard College Small molecule inhibitors of ebola and lassa fever viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2628199B2 (ja) 1988-09-26 1997-07-09 富士薬品工業株式会社 新規なアシルアミノ酸およびアシルペプチド化合物
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EP2607362B1 (en) * 2005-02-17 2014-12-31 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010075356A1 (en) * 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
GB201218084D0 (en) 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411909A1 (en) * 1989-07-31 1991-02-06 Merck & Co. Inc. Imidazole compounds and their use as transglutaminase inhibitors
US5721365A (en) * 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
WO1996030378A1 (en) * 1995-03-31 1996-10-03 Nippon Chemiphar Co., Ltd. Bisphosphonic acid derivatives
US6030946A (en) * 1995-06-07 2000-02-29 Axys Pharmaceuticals, Inc. Reversible cysteine protease inhibitors
EP0838460A1 (en) * 1995-07-13 1998-04-29 Senju Pharmaceutical Co., Ltd. Piperazine derivatives and use of the same
EP0771565A2 (en) * 1995-10-25 1997-05-07 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
CN1293666A (zh) * 1998-03-17 2001-05-02 阿斯特拉曾尼卡有限公司 苯硫酰胺衍生物及其作为药物的用途
WO2001007440A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Imidazoimidazoles and triazoles as anti-inflammatory agents
WO2004089470A2 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2013022550A2 (en) * 2011-08-10 2013-02-14 President And Fellows Of Harvard College Small molecule inhibitors of ebola and lassa fever viruses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CAS号: 1371000-53-1,1321660-27-8,1276484-50-4,1214799-76-4,338734-10-4,338733-99-6,337508-08-4;Chemical Abstracts Service;《Database Registry》;20120429;第5－8页 *
Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group;Takashi Kondo等;《Bioorganic & Medicinal Chemistry》;20071117;第16卷;第1613－1631页 *
PubChem CID: 3291454,3254510,55477654,42658068,42658077,51135247,5252414,52522415;Compound;《Database Pubchem》;20120125;全文 *
Structure-Activity Relationship Analysis of the Selective Inhibition of Transglutaminase 2 by Dihydroisoxazoles;R.Edward Watts等;《Journal of Medicinal Chemistry》;20061110;第49卷(第25期);第7493－7501页 *
Transglutaminase 2 inhibitors and their therapeutic role in disease states;Matthew Siegel等;《Pharmacology & Therapeutics》;20070513;第115卷(第2期);第232－245页 *
组织型谷氨酰胺转移酶抑制剂对凝血酶脑组织毒性的影响;黄亚林等;《卒中与神经疾病》;20060831;第13卷(第4期);第215－218页 *

Also Published As

Publication number Publication date
JP2015533154A (ja) 2015-11-19
EP2906543B1 (en) 2019-01-02
GB201218084D0 (en) 2012-11-21
US20150259310A1 (en) 2015-09-17
WO2014057266A1 (en) 2014-04-17
US9656978B2 (en) 2017-05-23
EP2906543A1 (en) 2015-08-19
JP6138950B2 (ja) 2017-05-31
CN104837821A (zh) 2015-08-12

Similar Documents

Publication Publication Date Title
CN104837821B (zh) 作为谷氨酰胺转移酶的抑制剂的酰基哌嗪类及其在药物中的用途
TWI781963B (zh) 含二硫化物細胞穿透肽及其製造與使用方法
US9605021B2 (en) Indoline compounds as granzyme B inhibitors
CN110088120A (zh) 转谷氨酰胺酶的抑制剂
AU642046B2 (en) N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors
AU2015207867A1 (en) Compounds and methods for the treatment of pain and other diseases
JP2024539150A (ja) 眼の状態を治療、予防、阻害、改善、又はその発症を遅延させるためのペプチド模倣物を含む方法及び組成物
CN104955806B (zh) 用于治疗骨关节炎的作为聚蛋白聚糖酶抑制剂的取代羧酸衍生物
JP2025504438A (ja) トランスグルタミナーゼの阻害剤
JP6612742B2 (ja) 関節症の処置のためのヒドロキシエチレン誘導体
JP2008019188A (ja) 新規カルノシン誘導体及び組成物
WO2014169697A1 (zh) 长春碱类衍生物及其制备方法和应用
AU2012216230B2 (en) Amino statin derivatives for the treatement of arthrosis
CN106316982B (zh) 噻嗪酰胺衍生物及其用途
JP6430936B2 (ja) 関節症の処置のためのヒドロキシスタチン誘導体
WO2020052509A1 (zh) 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CA2887420A1 (en) Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases
WO2025008627A1 (en) New compounds
CN118234705A (zh) 天冬氨酸的衍生物及其在肝纤维化、非酒精性肝炎等代谢等疾病的治疗的应用
WO2023246925A1 (zh) 酯类化合物及其应用
WO2023077977A1 (zh) 秋水仙碱衍生物的制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant